A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Topotecan (Primary)
- Indications Gynaecological cancer
- Focus Adverse reactions; Pharmacokinetics
- 05 Apr 2013 Biomarkers information updated
- 04 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2011 Planned end date changed from 1 Feb 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.